EpicentRx
CA - La Jolla
BiotechnologyFocus: Epigenetics, Oncolytic viruses
EpicentRx is a life sciences company focused on Epigenetics, Oncolytic viruses.
Rare Diseases
Funding Stage
PUBLIC
Open Jobs
0
Pipeline & Clinical Trials
PSV
CancerClinical Trials (1)
NCT03529539Expanded Access for PSV Personalized Oncolytic Viruses
N/ARRx-001
Brain Tumor, RecurrentClinical Trials (1)
NCT04525014RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors
Phase 1RRx-001
Malignant Solid TumorClinical Trials (1)
NCT02096341A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001
Phase 1RRx-001 dose escalation with TMZ + RT
GlioblastomaClinical Trials (1)
NCT02871843RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas
Phase 1RRx-001
Malignant Solid TumorClinical Trials (1)
NCT01359982Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects
Phase 1RRx-001
Malignant Solid TumorClinical Trials (1)
NCT02518958A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab
Phase 1RRx-001
Malignant Solid TumorClinical Trials (1)
NCT02801097RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)
Phase 1RRx-001 + WBRT
Brain MetastasesClinical Trials (1)
NCT02215512Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases
Phase 1RRx-001
Oral MucositisClinical Trials (1)
NCT05966194RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer
Phase 2RRx-001
CholangiocarcinomaClinical Trials (1)
NCT02452970RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy
Phase 2RRx-001
Small Cell CarcinomaClinical Trials (1)
NCT02489903RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
Phase 2RRx-001
Colorectal NeoplasmsClinical Trials (1)
NCT02096354A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
Phase 2AdAPT-001
Solid Tumor, AdultClinical Trials (1)
NCT04673942A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
Phase 2RRx-001
Oral MucositisClinical Trials (1)
NCT03515538Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers
Phase 2RRx-001 + eLOOP Device
Carcinoma, Small Cell LungClinical Trials (1)
NCT05566041A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer
Phase 3RRx-001 + eLOOP Device
Carcinoma, Small Cell LungClinical Trials (1)
NCT03699956RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer
Phase 3Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Founded: 2023
Portfolio: 16 clinical trials